4.6 Review

Considering TWEAK as a target for therapy in renal and vascular injury

期刊

CYTOKINE & GROWTH FACTOR REVIEWS
卷 20, 期 3, 页码 251-258

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2009.05.002

关键词

TWEAK; Fn14 receptor; Cytokines

资金

  1. ISCIIIRETICS REDINREN [FIS 06/0046, 06/0016]
  2. RECAVA [RD06/0014/0035]
  3. MEC [SAF03/884, SAF2007-60896, SAF2007/63648]
  4. Sociedad Espanola de Nefrologia [S2006/GEN-0247]
  5. Fondo de Investigaciones Sanitarias [CP04/00060]
  6. Comunidad de Madrid and FRACAM [S-BIO 0283/2006]

向作者/读者索取更多资源

TWEAK is a cytokine of the TNF superfamily that activates the Fn14 receptor. TWEAK may regulate cell proliferation, cell death, cell differentiation, angiogenesis and inflammation. The expression of TWEAK and Fn14 is increased during vascular and renal injury. Inflammatory cytokines increase Fn14 receptor expression in tubular and vascular smooth muscle cells. Moreover, TWEAK induces tubular cell apoptosis under proinflammatory conditions. TWEAK itself contributes to renal and vascular inflammation by promoting chemokine and inflammatory cytokine secretion. Confirmation of its role in acute kidney injury and atherosclerotic lesions formation came from functional studies in experimental animal models. The available evidence suggests that TWEAK might be a target for therapeutic intervention in renal and vascular injury and its role in different forms of tissue damage should be further explored. (C) 2009 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据